AI Article Synopsis
- Alpha1-antitrypsin (AAT) deficiency is a genetic condition often overlooked in people with chronic obstructive pulmonary disease (COPD), and this study aimed to assess its prevalence among Lithuanian COPD patients.
- A nationwide screening involved 1,167 patients, assessing AAT levels and genetic variants, revealing significant frequencies of AAT deficiency genotypes.
- The findings indicate a notable prevalence of certain AAT genotypes (like MZ, SZ, ZZ) in COPD patients, suggesting the need for improved awareness and targeted screening in Lithuania.
Article Abstract
Background: Alpha1-antitrypsin (AAT) deficiency is an under-diagnosed condition in patients with chronic obstructive pulmonary disease (COPD). The objective of the present screening was to estimate the AAT gene frequency and prevalence and to identify AAT deficiency cases in a large cohort of Lithuanian patients with COPD.
Methods: A nationwide program of AAT deficiency was conducted in 1167 COPD patients, defined according to the GOLD criteria. Patients were collected from outpatient clinics in five different Lithuanian regions (Kaunas, Vilnius, Siauliai, Klaipeda and Alytus). AAT serum concentrations were measured by nephelometry; PI-phenotypes characterized by isoelectric-focusing.
Results: Mean age and FEV(1) were 62.0 (10.3) and 54.7% (10.9), respectively. Ninety-one AAT deficiency genotypes (40 MZ, 39 MS, 1 SS, 3 SZ and 8 ZZ) were identified. Calculated PI(*)S and PI(*)Z frequencies, expressed in per 1000, were 18.8 (95% CI: 13.9-25) and 25.3 (95% CI: 19.4-32.7), respectively. The calculated AAT gene prevalence (Hardy-Weinberg principle) was: 1/1.09 for MM, 1/28 for MS, 1/2814 for SS, 1/20 for MZ, 1/1049 for SZ and 1/1565 for ZZ. Calculated Odds ratio (OR) for PI(*)Z in COPD vs. Lithuanian healthy people was of 1.87 (P=0.004).
Conclusion: The OR for each genotypic class demonstrated a significant increase of MZ, SZ and ZZ genotypes in COPD patients. The results of the present study, with a significant number of ZZ individuals detected, support the general concept of targeted screening for AAT deficiency in countries like Lithuania, with a large population of COPD patients and low awareness among care-givers about this genetic condition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rmed.2008.07.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Can Quality of Life Tests Be Useful in Patients Affected by Alpha-1 Antitrypsin Deficiency?
J Clin Med
December 2024
Evaluation Service of the Canarian Health Service, Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), 38001 Santa Cruz de Tenerife, Spain.
Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that predisposes a person to certain diseases over their lifetime, mainly including lung disease (in the form of emphysema) and liver disease (liver cirrhosis). Quality of life questionnaires are instruments designed to quantify the deterioration of a patient's health. : This study aimed to assess whether certain quality of life tests that are routinely used in clinical practice can be useful for patients with AATD.
View Article and Find Full Text PDFAuthors reply: Alpha-1 antitrypsin deficiency associated with increased risks of skin cancer, leukemia, and hepatic cancer: A nationwide cohort study.
J Intern Med
December 2024
Department of Clinical Biochemistry, Zealand University Hospital, Køge, Denmark.
Regarding: Alpha-1 antitrypsin deficiency associated with increased risks of skin cancer, leukemia, and hepatic cancer: A nationwide cohort study.
J Intern Med
December 2024
Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany.
Alpha-1 antitripsyn deficiency and augmentation therapy in pregnancy: two case reports.
Front Med (Lausanne)
December 2024
Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', AORN Ospedali dei Colli, Naples, Italy.
Alpha-1 antitrypsin deficiency (AATD) is an inherited condition characterized by reduced plasma levels of alpha-1 antitrypsin (AAT), often leading to pulmonary diseases primarily emphysema and/or chronic obstructive pulmonary disease (COPD), but also bronchiectasis, bronchial asthma, or other less common disorders. Early diagnosis enables AAT augmentation therapy, which has proven to be effective in slowing down functional decline and improving survival rates. This article presents two cases of pregnant women with rare allelic variants of AATD who received AAT augmentation therapy, exploring the limited evidence on its safety during pregnancy and the potential role of decreased serum AAT levels in pregnancy-related complications.
View Article and Find Full Text PDFClinical implications of the SERPINA1 variant, M, and alpha-1 antitrypsin deficiency in Türkiye.
BMC Pulm Med
December 2024
School of Medicine, Department of Chest Diseases, Recep Tayyip Erdoğan University, Rize, Turkey.
Background: Alpha-1 antitrypsin deficiency (AATD) is associated with increased susceptibility to chronic obstructive pulmonary disease (COPD). AATD results from mutations in the SERPINA1 gene and over 500 rare mutations have been identified. Despite these findings and recommendations from major healthcare organizations, testing of COPD patients and their family members for AATD remains inadequate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!